Design and production of a novel IL-2v conjugated trispecific antibody targeting CD19 for B-cell Lymphoma treatment
Large B cell lymphoma is one of the most common lymphomas. While most newly diagnosed patients achieve long term remission and cure, the prognosis of relapsed or refractory disease remains poor.
Bispecific antibodies are a promising tool for the treatment of relapsed or refractory large B cell lymphoma. They are able to bring immune effector cells into close proximity of tumor cells and facilitate the formation of an immune synapse leading to tumor cell lysis.
Our aim is to further improve the efficacy of CD19-targeting bispecific antibodies by adding an additional functional domain to obtain a third function. This could, for example, be a modified cytokine.